文献速递胸部肿瘤

晚期肺癌循环游离DNA全面基因组检测的临床影响

The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2018-08-16

该回顾性研究纳入2014至2017年以色列116例IIIB/IV期NSCLC患者,采用cfDNA NGS(Guardant360)检测可靶向基因组改变。31%初治前、32.5%化疗或免疫进展后、71%EGFR-TKI进展后患者检出可靶向改变,26%患者治疗决策改为靶向治疗,客观缓解率43%,疾病控制率75%,中位治疗持续时间5个月。

要点

  • cfDNA NGS在初治前、化疗或免疫进展后、EGFR-TKI进展后分别有31%、32.5%、71%检出可靶向改变。
  • 26%(30/116)患者基于cfDNA结果将治疗决策改为靶向治疗。
  • 客观缓解率43%,疾病控制率75%,中位治疗持续时间5个月。

核心结论

  • 全面cfDNA检测在晚期NSCLC患者中影响约四分之一至三分之一的初始及后续治疗决策。
  • 基于cfDNA的靶向治疗反应持久,并可在初诊和进展时改变治疗决策。

研究设计与样本

  • 回顾性研究,纳入2014至2017年以色列IIIB/IV期NSCLC患者,使用cfDNA NGS(Guardant360)检测可靶向基因组改变。
  • 连续检测116例患者:41.4%在一线治疗前(A组),34.5%在化疗或免疫治疗进展后(B1组),24.1%在EGFR酪氨酸激酶抑制剂进展后(B2组)。

主要发现

  • A组31%(15/48)检出可靶向基因组改变,B1组32.5%(13/40),B2组71%(20/28)。
  • 治疗决策改为靶向治疗的比例分别为A组23%(11/48)、B1组25%(10/40)、B2组32%(9/28),总队列26%(30/116)。
  • 客观缓解率(RECIST)为43%(12/28),其中完全缓解1例,部分缓解39%(11/28),疾病稳定32%(9/28),疾病进展25%(7/28)。
  • 疾病控制率为75%,中位治疗持续时间5个月。

临床怎么用

  • 对晚期NSCLC患者,可在初治前及化疗、免疫或EGFR-TKI进展后行cfDNA NGS检测可靶向基因组改变以指导靶向治疗决策。

局限性

  • 为回顾性研究,样本量有限(116例),部分亚组样本量较小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Next-generation sequencing (NGS) of cell-free circulating tumor DNA (cfDNA) enables noninvasive genomic analysis of NSCLC patients. Although plasma-detected genomic alterations (GAs) have been shown to predict targeted therapy response, evidence of durability of response is lacking or limited to small cohorts as is the impact of cfDNA NGS results on clinical decisions. METHODS: This retrospective study of stage IIIB/IV NSCLC patients between the years 2014 and 2017 in Israel used cfDNA NGS (Guardant360; Guardant Health, Inc., Redwood City, California) to identify targetable GAs. RESULTS: We consecutively tested 116 NSCLC patients, 41.4% before first-line therapy (group A), 34.5% upon progression on chemotherapy or immunotherapy (group B1), and 24.1% upon progression on EGFR tyrosine kinase inhibitors (group B2). Targetable GAs were found in 31% of group A (15 of 48 patients), 32.5% in group B1 (13 of 40 patients) and 71% in group B2 (20 of 28 patients). Treatment decision was changed to targeted therapy in 23% (11 of 48 patients), 25% (10 of 40 patients) and 32% (9 of 28 patients), respectively (total cohort 26%; 30/116). Objective response rate (Response Evaluation Criteria in Solid Tumors) was 43% (12 of 28 patients) including one complete response, partial response in 39% (11 of 28 patients), stable disease in 32% (9 of 28 patients), and progressive disease in 25% (7 of 28 patients). Disease control rate was 75% for 5 months median treatment duration. CONCLUSIONS: Comprehensive cfDNA testing impacted clinical decisions in one-quarter to one-third of initial and subsequent lines of treatment in advanced NSCLC patients. This retrospective study extends previous reports by showing that responses based on cfDNA are durable and change treatment decisions at initial presentation and at progression.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Laufer-Geva S, Rozenblum AB, Twito T, et al. The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer. J Thorac Oncol. 2018. PMID: 30121392. doi:10.1016/j.jtho.2018.07.101

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。